| Delivery of oligonucleotides to the liver with GalNAc: from research to registered therapeutic drug AJ Debacker, J Voutila, M Catley, D Blakey, N Habib Molecular Therapy 28 (8), 1759-1771, 2020 | 265 | 2020 |
| Heavily and fully modified RNAs guide efficient SpyCas9-mediated genome editing A Mir, JF Alterman, MR Hassler, AJ Debacker, E Hudgens, D Echeverria, ... Nature Communications 9 (1), 2641, 2018 | 110 | 2018 |
| Innovative developments and emerging technologies in RNA therapeutics F Halloy, A Biscans, KE Bujold, A Debacker, AC Hill, A Lacroix, O Luige, ... RNA biology 19 (1), 313-332, 2022 | 31 | 2022 |
| Locked nucleic acid gapmers and conjugates potently silence ADAM33, an asthma-associated metalloprotease with nuclear-localized mRNA HM Pendergraff, PM Krishnamurthy, AJ Debacker, MP Moazami, ... Molecular Therapy-Nucleic Acids 8, 158-168, 2017 | 25 | 2017 |
| Single-stranded silencing RNAs: hit rate and chemical modification HM Pendergraff, AJ Debacker, JK Watts nucleic acid therapeutics 26 (4), 216-222, 2016 | 25 | 2016 |
| Intratracheally administered LNA gapmer antisense oligonucleotides induce robust gene silencing in mouse lung fibroblasts M Shin, IL Chan, Y Cao, AM Gruntman, J Lee, J Sousa, TC Rodríguez, ... Nucleic Acids Research 50 (15), 8418-8430, 2022 | 23 | 2022 |
| Next-generation Peptide Nucleic acid chimeras exhibit high affinity and potent gene silencing AJ Debacker, VK Sharma, P Meda Krishnamurthy, D O’Reilly, R Greenhill, ... Biochemistry 58 (6), 582-589, 2018 | 12 | 2018 |
| Voutila J. Catley M. Blakey D AJ Debacker Habib N. Mol. Ther 28, 1759-1771, 2020 | 5 | 2020 |
| Modified guide rnas for crispr genome editing EJ Sontheimer, A Khvorova, JK Watts, A Mir, JF Alterman, MR Hassler, ... US Patent App. 16/981,908, 2021 | 3 | 2021 |
| Double stranded nucleic acid compounds inhibiting zpi A Mccarthy, G Craggs, J Longden, I De Santiago, D Brown, AA Mortazavi, ... US Patent App. 18/624,912, 2024 | | 2024 |
| Inhibitors of expression and/or function AV Whitmore, J Borgel, A Mccarthy, G Craggs, J Longden, I De Santiago, ... US Patent App. 18/640,905, 2024 | | 2024 |
| TMEM173 saRNA Compositions and Methods of Use CP Tan, L Sinigaglia, VG Martinez, B Ryan, P Saetrom, SA Hegre, ... US Patent App. 18/282,402, 2024 | | 2024 |
| Oligonucleotide conjugate compositions and methods of use A Debacker, J Voutila, L Mitchell, CM McKeen US Patent App. 17/636,437, 2022 | | 2022 |
| Sirt1-sarna compositions and methods of use P Andrikakou, A Debacker, V Reebye US Patent App. 17/603,204, 2022 | | 2022 |
| Novel approach for upregulation of endogenous immunostimulatory targets for cancer therapy. CP Tan, L Sinigaglia, SA Hegre, A Debacker, A Kwok, P Saetrom, ... CANCER IMMUNOLOGY RESEARCH 8 (3), 67-67, 2020 | | 2020 |
| Locked Nucleic Acid gapmers and conjugates induce potent silencing of ADAM33, an asthma-associated metalloprotease with nuclear-localized mRNA HM Pendergraff, PM Krishnamurthy, AJ Debacker, M Moazami, ... Molecular Therapy: Nucleic Acid, 2017 | | 2017 |
| Improving gene silencing oligonucleotides by incorporation of peptide nucleic acids AJ Debacker University of Southampton, 2017 | | 2017 |
